Rapamycin for Longevity — Largest Preclinical Lifespan Signal in Mammals

Rapamycin is the most-studied small molecule for lifespan extension in mammals. It produces a 9–14% median lifespan extension in mice across multiple cohorts. Used off-label in human longevity protocols at 5–6 mg weekly with washout periods. NexLife's longevity program includes compounded rapamycin under physician oversight.

The strongest mammalian lifespan-extension signal

Rapamycin (sirolimus) was the first small molecule shown to extend median lifespan in mice when started in late life (NIA Interventions Testing Program, Harrison et al., Nature 2009). The 9–14% median lifespan extension has been replicated across multiple mouse cohorts and remains the largest lifespan-extension signal for any small molecule in mammals.

Mechanism — mTORC1 inhibition

Rapamycin binds FKBP12 and the complex inhibits mTORC1 (mechanistic target of rapamycin complex 1). mTORC1 is a central nutrient and growth-signaling kinase; its inhibition promotes autophagy, reduces protein synthesis, and shifts cells toward maintenance and repair.

Off-label longevity protocols

Used off-label in human longevity programs at 5–6 mg weekly oral, with washout periods. Some clinicians use 3 mg every other week or longer cycles. The cyclical / pulsed dosing approach aims to capture mTOR inhibition while minimizing immunosuppressive side effects associated with continuous dosing in transplant patients.

Trial landscape — PEARL and beyond

The PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial — Phase 2 RCT, 6 mg/week × 48 weeks — is investigating rapamycin's effect on age-related biomarkers. Additional trials are emerging in cardiovascular and immune endpoints.

NexLife longevity program

NexLife's longevity program at $129/mo includes compounded rapamycin under physician oversight by Medical Director Adam Kennah, M.D.. Protocols are individualized; dosing and washout schedules are reviewed by the prescribing provider.

Sources

• Harrison DE et al., Rapamycin lifespan extension — Nature 2009
• Mannick JB et al., Rapamycin and immune function — Sci Transl Med 2014
• PEARL trial registration — clinicaltrials.gov